Last reviewed · How we verify
Multi-Phenolic (PYRROLE)
At a glance
| Generic name | PYRROLE |
|---|---|
| Sponsor | Energique, Inc. |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- rash
- fatigue
- lack of concentration
Common side effects
Key clinical trials
- EFFECTS OF PYRROLOQUINOLINE QUINONE (PQQ) SUPPLEMENTATION ON NON-ENDURANCE TRAINED ATHLETES (NA)
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
- Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck (PHASE2)
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer (PHASE1,PHASE2)
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Mozambique
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multi-Phenolic CI brief — competitive landscape report
- Multi-Phenolic updates RSS · CI watch RSS
- Energique, Inc. portfolio CI